Estrogen signaling drives proliferation in the 60–70% of breast cancers that express the estrogen receptor, and adjuvant anti-estrogen therapy is prescribed to the majority of these patients to prevent breast cancer recurrence. The gene discussed is ESR1; the disease is breast cancer.